{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:35:40Z","timestamp":1793208940687,"version":"4.5.0"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":106,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe program","doi-asserted-by":"publisher","award":["101095479"],"award-info":[{"award-number":["101095479"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EUROPA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the cost-effectiveness of guideline-directed medical treatments for heart failure with reduced ejection fraction (HFrEF) by performing a network meta-analysis (NMA) of randomized controlled trials (RCTs) feeding a subsequent cost-effectiveness analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A random-effects NMA of RCTs was conducted. The primary analysis included only RCTs evaluating drugs in clinical settings as recommended in the 2021 European Society of Cardiology HF guidelines. Main efficacy outcomes included all-cause mortality (ACM) and total HF hospitalizations (HFH). A decision tree-Markov model was populated with NMA-derived efficacy estimates, quality-of-life data, and costs from United Kingdom (UK, main analysis), as well as Sweden and United States (US) (scenario analyses) healthcare perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 47 RCTs (75 978 patients) were included. The risk of ACM and total HFH decreased with increasing number of pharmacological treatments. In the main (UK) analysis, the greatest benefit was observed with a quadruple therapy including angiotensin receptor\u2013neprilysin inhibitor (ARNI) + \u03b2-blocker (BB) + mineralocorticoid receptor antagonist (MRA) + sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i), which resulted as the most cost-effective strategy (12.31 quality-adjusted life-years; net monetary benefit of \u00a3338 460; UK perspective). Findings were consistent in Sweden and USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Quadruple therapy with ARNI + BB + MRA + SGLT2i had the highest probability of being the most cost-effective strategy. Our findings might inform future health economic policies and reimbursement decisions, while also considering affordability, budget impact, and implementation feasibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag233","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:50:26Z","timestamp":1784116226000},"page":"646-659","source":"Crossref","is-referenced-by-count":1,"title":["A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF"],"prefix":"10.1093","volume":"28","author":[{"given":"Renzo","family":"Laborante","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Galway , Galway ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt N","family":"Beer","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]},{"name":"Department of Cardiology, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site North , Hamburg ,","place":["Germany"]},{"name":"INSERM, INRAE, Centre for Research in Epidemiology and Statistics (CRESS), Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-5550","authenticated-orcid":false,"given":"Valeria","family":"Valente","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Mavridis","sequence":"additional","affiliation":[{"name":"Department of Primary Education, School of Education, University of Ioannina , Ioannina ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Di Bidino","sequence":"additional","affiliation":[{"name":"Graduate School of Health Economics and Management, Universit\u00e0 Cattolica del Sacro Cuore (ALTEMS) , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Novara ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit","family":"Roes","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center Department of Health Evidence, Section Biostatistics, , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Basile","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]},{"name":"ANMCO Research Center, Heart Care Foundation , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-0697","authenticated-orcid":false,"given":"Carin","family":"Corovic Cabrera","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4781-9588","authenticated-orcid":false,"given":"Raffaele","family":"Scorza","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-4679","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Porcher","sequence":"additional","affiliation":[{"name":"INSERM, INRAE, Centre for Research in Epidemiology and Statistics (CRESS), Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord , Paris ,","place":["France"]},{"name":"Centre D'\u00c9pid\u00e9miologie Clinique, AP-HP, H\u00f4pital H\u00f4tel-Dieu , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Temple, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2026102813150964900_xuag233-B1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ejhf\/xuag121","article-title":"The global epidemiology of heart failure: a comprehensive and contemporary review","volume":"28","author":"Valente","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B2","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.jacc.2025.08.054","article-title":"Pharmacologic treatment of heart failure with reduced ejection fraction: an updated systematic review and network meta-analysis","volume":"86","author":"van Essen","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026102813150964900_xuag233-B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102684","article-title":"The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021","volume":"49","author":"ElSaygh","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2026102813150964900_xuag233-B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12962-023-00436-w","article-title":"What are economic costs and when should they be used in health economic studies?","volume":"21","author":"Turner","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"key":"2026102813150964900_xuag233-B5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026102813150964900_xuag233-B6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jrsm.1700","article-title":"Twenty years of network meta-analysis: continuing controversies and recent developments","volume":"15","author":"Ades","year":"2024","journal-title":"Res Synth Methods"},{"key":"2026102813150964900_xuag233-B7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"key":"2026102813150964900_xuag233-B8","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102813150964900_xuag233-B9","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102813150964900_xuag233-B10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"2026102813150964900_xuag233-B11","author":"NICE health technology evaluations: the manual 2025"},{"key":"2026102813150964900_xuag233-B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026102813150964900_xuag233-B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"2026102813150964900_xuag233-B14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"2026102813150964900_xuag233-B15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1161\/CIRCULATIONAHA.121.053659","article-title":"Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2026102813150964900_xuag233-B16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102813150964900_xuag233-B17","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102813150964900_xuag233-B18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ejhf.3218","article-title":"Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction\u2014results from the EMPULSE trial","volume":"26","author":"Tromp","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026102813150964900_xuag233-B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04406-6","article-title":"Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial","volume":"32","author":"van Veldhuisen","year":"2026","journal-title":"Nat Med"},{"key":"2026102813150964900_xuag233-B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026102813150964900_xuag233-B22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"2026102813150964900_xuag233-B23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"key":"2026102813150964900_xuag233-B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026102813150964900_xuag233-B25","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"2026102813150964900_xuag233-B26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ejhf.2486","article-title":"The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF","volume":"24","author":"DeVore","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis","volume":"23","author":"Turgeon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjcvp\/pvad088","article-title":"Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Oriecuia","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026102813150964900_xuag233-B29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026102813150964900_xuag233-B30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"2026102813150964900_xuag233-B31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"2026102813150964900_xuag233-B32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cardfail.2013.05.016","article-title":"National patterns of heart failure hospitalizations and mortality by sex and age","volume":"19","author":"Rodriguez","year":"2013","journal-title":"J Card Fail"},{"key":"2026102813150964900_xuag233-B33","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.122.059282","article-title":"Health status trajectories before and after hospitalization for heart failure","volume":"145","author":"Vaduganathan","year":"2022","journal-title":"Circulation"},{"key":"2026102813150964900_xuag233-B34"},{"key":"2026102813150964900_xuag233-B35","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2025-327190","article-title":"Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction","author":"Mariani","year":"2026","journal-title":"Heart"},{"key":"2026102813150964900_xuag233-B36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag199","article-title":"Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription","author":"Lindberg","year":"2026","journal-title":"Eur Heart J"},{"key":"2026102813150964900_xuag233-B37","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026102813150964900_xuag233-B38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"2026102813150964900_xuag233-B39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"2026102813150964900_xuag233-B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"2026102813150964900_xuag233-B41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026102813150964900_xuag233-B42","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.jacc.2025.08.054","article-title":"Pharmacologic treatment of heart failure with reduced ejection fraction","volume":"86","author":"van Essen Bart","journal-title":"JACC"},{"key":"2026102813150964900_xuag233-B43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/joim.13487","article-title":"Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction","volume":"292","author":"De Marzo","year":"2022","journal-title":"J Intern Med"},{"key":"2026102813150964900_xuag233-B44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026102813150964900_xuag233-B45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026102813150964900_xuag233-B46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","article-title":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"42","author":"Packer","year":"2021","journal-title":"Eur Heart J"},{"key":"2026102813150964900_xuag233-B47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of dapagliflozin in patients with HFrEF treated with sacubitril\/valsartan: the DAPA-HF trial","volume":"8","author":"Solomon","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026102813150964900_xuag233-B48","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/ejhf.2608","article-title":"Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan: insights from the VICTORIA trial","volume":"24","author":"Senni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B49","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B50","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/CIRCULATIONAHA.122.063602","article-title":"Cost-effectiveness of vericiguat in patients with heart failure with reduced ejection fraction: the VICTORIA randomized clinical trial","volume":"148","author":"Chew","year":"2023","journal-title":"Circulation"},{"key":"2026102813150964900_xuag233-B51","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jchf.2023.01.004","article-title":"Cost-effectiveness of comprehensive quadruple therapy for heart failure with reduced ejection fraction","volume":"11","author":"Dixit","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026102813150964900_xuag233-B52","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026102813150964900_xuag233-B53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7326\/M16-0057","article-title":"Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction","volume":"165","author":"Sandhu","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026102813150964900_xuag233-B54","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1002\/ehf2.14767","article-title":"Eligibility for vericiguat in a real-world, contemporary heart failure population","volume":"11","author":"Vergaro","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026102813150964900_xuag233-B55","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/ejhf.2939","article-title":"Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: data from the Swedish Heart Failure Registry","volume":"25","author":"Nguyen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B56","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1016\/j.jacc.2022.04.031","article-title":"Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure","volume":"79","author":"Faridi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026102813150964900_xuag233-B57","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B58","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","article-title":"Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026102813150964900_xuag233-B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026102813150964900_xuag233-B60","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/eurheartj\/ehac103","article-title":"Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction","volume":"43","author":"Tromp","year":"2022","journal-title":"Eur Heart J"},{"key":"2026102813150964900_xuag233-B61","doi-asserted-by":"publisher","DOI":"10.1093\/ejhf\/xuag142","article-title":"Bridging the gap: adapting heart failure guidelines for resource-limited settings: a European Journal of Heart Failure expert consensus document","author":"Abdin","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B62","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1002\/ejhf.70090","article-title":"Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy","volume":"27","author":"Savarese","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026102813150964900_xuag233-B63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.healthpol.2017.02.008","article-title":"Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure","volume":"121","author":"Gourzoulidis","year":"2017","journal-title":"Health Policy"},{"key":"2026102813150964900_xuag233-B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16290","article-title":"Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes","volume":"6","author":"Essien","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026102813150964900_xuag233-B65","doi-asserted-by":"publisher","DOI":"10.1093\/eschf\/xvag018","article-title":"Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials","volume":"13","author":"Laborante","year":"2026","journal-title":"ESC Heart Fail"},{"key":"2026102813150964900_xuag233-B66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejim.2025.01.014","article-title":"Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials","volume":"135","author":"Laborante","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2026102813150964900_xuag233-B67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag233\/69071062\/xuag233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/646\/69071062\/xuag233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/4\/646\/69071062\/xuag233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:15:15Z","timestamp":1793207715000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/4\/646\/8736025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,16]]},"published-print":{"date-parts":[[2026,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag233","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]}}}